Merck (MRK) Tops Q1 EPS by 5c; Offers FY23 Guidance

Merck (NYSE: MRK) reported Q1 EPS of $1.40, $0.05 better than the analyst estimate of $1.35. Revenue for the quarter came in at $0 versus the consensus estimate of $13.78 billion.

GUIDANCE:

Merck sees FY2023 EPS of $6.88-$7.00, versus the consensus of $6.91. Merck sees FY2023 revenue of $57.7-58.9 billion, versus the consensus of $58.3 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Calamp Corp. (CAMP) Misses Q2 EPS by 33c